In an editorial in CNS Spectrums, Dr. Jay Avasarala advocates for increased minority representation in clinical trials for MS drugs. Photo | Mark Mahan
LEXINGTON, Ky. (April 2, 2021) In an editorial recently published in CNS Spectrums, Dr. Jay Avasarala continues to raise a concern he voiced in a previous writing published about two years ago. The question at the center of his editorials – “When will we achieve racial parity?”
Avasarala, director of UK HealthCare’s Multiple Sclerosis Center within the Kentucky Neuroscience Institute, says enrollment of people of color in pivotal trials for multiple sclerosis (MS) and neuromyelitis spectrum disorder (NMOSD) continues to be dismal.